Drug Trial Radar · NCT03155061
Study of ONO-4578 With and Without ONO-4538 in Subjects Advanced or Metastatic Solid Tumors
Last checked: Nov 20, 2026Latest source record: Sep 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
183
Planned (sponsor's estimate)
Start
Apr 19, 2017
Primary completion
Mar 2028
Study completion Mar 2028
Sponsor
- Lead sponsor
- Ono Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- May 16, 2017
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 20 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of the study is to evaluate the safety, tolerability, pharmacokinetics, efficacy and biomarker of ONO-4578 and combinations of ONO-4578 and ONO-4538 in subjects with advanced or metastatic solid tumors and subjects with unresectable, advanced or recurrent gastric cancer, unresectable, advanced or recurrent colorectal cancer.
Conditions
- Advanced or Metastatic Solid Tumors
Interventions
ONO-4578Drug
ONO-4578 specified dose on specified days
ONO-4538Drug
ONO-4538 specified dose on specified days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Evaluation of the safety (adverse event, clinical laboratory test, 12-lead electrocardiography, chest X-ray, ECOG performance status)Time frame: Through study completion, an average of 1 year
Locations
22 sites in 1 country. Site status is shown where the registry gives one.
Aichi Clinical Site 1
Nagoya, Aichi-ken, Japan
Aichi Clinical Site 2
Toyoake, Aichi-ken, Japan
Chiba Clinical Site 1
Kashiwa, Chiba, Japan
Ehime Clinical Site1
Matsuyama, Ehime, Japan
Fukuoka Clinical Site 1
Fukuoka, Fukuoka, Japan
Fukuoka Clinical Site 2
Fukuoka, Fukuoka, Japan
Gunma Clinical Site 1
Ōta, Gunma, Japan
Hokkaido Clinical Site 1
Sapporo, Hokkaido, Japan
Iwate Clinical Site 1
Yahaba-cho, Iwate, Japan
Kanagawa Clinical Site 2
Sagamihara, Kanagawa, Japan
Kanagawa Clinical Site 1
Yokohama, Kanagawa, Japan
Osaka Clinical Site 2
Hirakata, Osaka, Japan
Osaka Clinical Site 1
Osaka, Osaka, Japan
Osaka Clinical Site 3
Sakai, Osaka, Japan
Osaka Clinical Site 4
Takatsuki, Osaka, Japan
Saitama Clinical Site 2
Hidaka, Saitama, Japan
Saitama Clinical Site 1
Ina-machi, Saitama, Japan
Shizuoka Clinical Site 1
Nagaizumi-Cho, Shizuoka, Japan
Tokyo Clinical Site 1
Chuo-ku, Tokyo, Japan
Tokyo Clinical Site 2
Koto-ku, Tokyo, Japan
Tokyo Clinical Site 3
Shinjyuku-ku, Tokyo, Japan
Tokyo Clinical Site 4
tabashi City, Tokyo, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.